Novo Nordisk A/S is a global healthcare company founded in 1989 through the merger of two Danish pharmaceutical companies with roots dating back to the 1920s. Headquartered in Bagsværd, Denmark, the company employs more than 69,000 people in 80 offices around the world. In 2024, Novo Nordisk generated approximately $42.1 billion in revenue.
The company is a global healthcare company with more than 100 years of innovation and leadership in serious chronic disease treatment. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices, including its flagship products Ozempic and Wegovy. The company markets its products in 168 countries.
Recent leadership news
In July 2025, Novo Nordisk appointed Maziar Mike Doustdar as President and CEO, succeeding Lars Fruergaard Jørgensen who led the company for 34 years. Doustdar announced a restructuring plan to save approximately $1.3 billion annually by late 2026, involving roughly 9,000 employee layoffs.
This is an automatically generated Light company page created by Executive Moves editorial systems from verified public announcements. Information is kept deliberately concise until the page is claimed and enriched.
Facts compiled by Executive Moves from publicly available news and press releases on 10 June 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the Novo Nordisk team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
